In this study, the doctors will follow a set of rules that is called an algorithm. An algorithm is a step-by-step approach that doctors use to guide them when making decisions about the best way to treat their patients. Algorithms are useful because they help doctors decide on the best treatment approach based on the patient's individual circumstances and the best medical evidence available. The algorithm that is being used in this study is called a calcium modification algorithm and it will guide doctors when deciding on the best way to modify or break up the calcium in coronary arteries. In this study, we aim to prove that the calcium modification algorithm, described above, safely and effectively guides doctors on the best way to modify calcium in patients' coronary arteries. By doing so, it will help doctors in making decisions about patients' treatment during their procedure. It will also help standardise care for patients, so patients receive the same treatment no matter what hospital they are in or what doctor is treating them.
Investigational strategy: Calcium modification algorithm to guide coronary intervention with an High Definition Intra Vascular Ultrasound (HD IVUS) imaging guided pathway that provides a systematic approach to coronary modification. Objectives: The aim of this study is to validate a comprehensive and intravascular imaging-based calcium modification algorithm for the treatment of moderate to severely calcified coronary lesions. Study Population: Patients with coronary artery disease with evidence of moderate to severely calcified coronary arterial lesions that are planned for percutaneous intervention requiring calcium modification. Design: CYCLOPES is a prospective, multicenter, open-label, single arm trial assessing the feasibility and efficacy of an intracoronary ultrasound guided algorithm for calcium modification in patients undergoing percutaneous coronary intervention (PCI) for chronic calcific coronary artery disease. The study will enrol 500 patients who will undergo PCI with calcium modification. Participants will be enrolled prospectively in 25 sites in Ireland, Switzerland, the United Kingdom, Spain, France, Italy and Germany (7 countries). All patients will have coronary angiography (QCA) and intravascular ultrasound (IVUS) imaging with 60MHz HD IVUS of the calcified lesion at baseline. The lesion will be characterized based on calcium distribution and morphology as assessed by HD IVUS. Depending on the specific lesion characteristics, the appropriate method for calcium modification will be chosen and performed in line with the CYCLOPES calcium modification algorithm included in the study protocol. The calcific lesion will be imaged for a second time by 60MHz HD IVUS following calcium modification. The operator will then proceed, if no further lesion preparation is required, to deploy a bioabsorbable polymer Everolimus eluting stent using standard stenting techniques, post dilatation will be performed at the operator's discretion. The treated lesion will be assessed again using intravascular ultrasound following stent deployment and optimization. The primary end points will be the post stenting minimal stent area (MSA) at the site of maximum calcification relative to reference lumen area assessed with 60MHz HD IVUS and target lesion failure (TLF) at 1-year post-procedure. All HD IVUS determined endpoints will be assessed at an independent imaging core laboratory. Participants will be assessed with clinic or phone visits at hospital discharge, 1 month and 12-month time points post procedure.
Study Type
OBSERVATIONAL
Enrollment
500
Patients will undergo one or more of the following procedures, subject to the algorithm: Angioplasty Balloon Cutting Balloon Rotational Atherectomy Intravascular Lithotripsy
Mater Private Hospital
Dublin, Ireland
RECRUITINGMinimum stent area (MSA)
Minimum stent area (MSA) at the site of maximum calcification measured at the end of the index procedure
Time frame: End of Index Procedure
Target lesion failure (TLF)
Target lesion failure (TLF) (cardiovascular death, non-fatal myocardial infarction (MI) related to the target vessel, unplanned ischemia-driven target lesion revascularization) at 1 year
Time frame: At Year 1
Individual components of TLF at 1 month and 1 year
Individual components of TLF at 1 month and 1 year
Time frame: At 1 month and 1 year
Minimum stent area (MSA) at the end of the index procedure
Minimum stent area (MSA) at the end of the index procedure
Time frame: At end of index procedure
Strategy Success
Strategy success defined as: 1. Successful stent delivery 2. ≥ 80% stent expansion 3. Complete stent apposition 4. No edge dissection 5. Full lesion coverage with \<50% plaque burden at proximal and distal references 6. TIMI 3 flow
Time frame: At end of index procedure
Target vessel revascularization (TVR)
Target vessel revascularization (TVR)
Time frame: At Year 1
Target lesion revascularization (TLR)
Target lesion revascularization (TLR)
Time frame: At Year 1
Stent thrombosis
Stent thrombosis
Time frame: At Year 1
Stroke
Stroke
Time frame: At Year 1
Cardiovascular death
Cardiovascular death
Time frame: At Year 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.